Pancreatic tumours, on the other hand, are more uniform with PDAC accounting for most (95%) pancreatic tumours and is predominantly characterized by dysfunctioning (by mutation) of the KRAS oncogene and of the CDKN2A, SMAD4 and TP53 tumour-suppressor genes [16]. The gene discussed is CDKN2A; the disease is pancreatic neoplasm.